Ulrich Wagner
Papers
1
Total Citations
28
H-Index
1
About
Ulrich Wagner is a leading oncologic researcher whose work centers on rare genitourinary malignancies and the molecular mechanisms driving treatment resistance. His most impactful contributions lie in the study of inflammatory myofibroblastic tumors (IMTs), particularly those harboring ALK gene fusions. In his highly cited 2020 study, Wagner documented a case of an unresectable bladder IMT with a rare FN1-ALK fusion, demonstrating a differential response to the ALK inhibitor crizotinib. This work, which has garnered 28 citations, provided critical insight into how specific fusion partners can dictate therapeutic efficacy—a finding with direct implications for precision oncology in rare tumors. Beyond this, Wagner’s research portfolio explores the intersection of tumor biology and targeted therapy, often focusing on how genomic alterations can be exploited for clinical benefit. His findings have helped shape treatment paradigms for patients with limited options, underscoring the importance of molecular profiling in uncommon cancers. Through his meticulous case-based research, Wagner continues to advance the field of personalized medicine, offering hope for improved outcomes in challenging oncologic scenarios.
Research Focus
Key Achievements
Top Papers
- 1